|Topic:||Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease|
THE NATIONAL ACADEMIES
Institute of Medicine
Board on Health Care Services
Board on Health Sciences Policy
Food and Nutrition Board
Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease
607 Hart Senate Office Bldg. – 1: 00 p.m.
2123 Rayburn House Office Bldg. – 2:30 p.m.
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
This new report, from the Institute of Medicine, discusses how food manufacturers make health claims for many products and recommends that the FDA adopt a rigorous scientific process to evaluate biomarkers and vet these claims.
These series of briefings were for members of Congress and congressional staff only. The report was publicly released on May 12, 2010 and can be found, in its entirety, on the Web site of the National Academies Press.